ClinicalTrials.gg
Enrolling by invitationNCT06273982STEP-UPUpdated Nov 17, 2026

Behavioral Telehealth in Low-resource Primary Care Settings for Anxiety and Depression in Youth

An interventional study of STEP-UP (transdiagnostic behavioral therapy for pediatric anxiety and depression) and ARC (assisted referral to community care) in Depression, Anxiety, sponsored by San Diego State University. Enrolling by invitation at 1 site in United States. Open to participants aged 8 Years to 16 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by San Diego State University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
8 Years to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 3,715 studies in Depression with a site in United States — 579 open to participants now, 716 under way, 29 of them phase 3. Depression · United States.

Planned enrollment
749th of 3,322
220 · median 72
Started
2024
with 212 others
No phase
2,221 of 3,715
386 open now
Primary completion
2028-05
later than 517 of 714 live
Registered
3,189th of 3,715
by date

Among the 3,715 studies in Depression with a site in United States, this one is the 749th largest by planned enrollment of the 3,322 interventional ones that give a count, is one of 213 that started in 2024, is one of 2,221 with no phase, reaches primary completion later than 517 of the 714 other live ones, and was the 3,189th registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

579 of the 3,715 studies in Depression with a site in United States are open now. Recruiting first, the newest first:

574 more — sign in →

All 579 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 8 Years to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,715 studies in Depression with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to test a brief, behavioral telehealth treatment program (STEP-UP) for depression and anxiety in youths (age 8-16 years old). Youths and families will be recruited through participating community health centers and will be randomly assigned to either: (a) receive STEP-UP care from providers at their health center or (b) be referred to care from local community mental health clinicians. Youth and families will be interviewed before treatment starts, 16 weeks later, and 32 weeks later to assess how youth are feeling. The main question the study aims to answer is whether STEP-UP improves youths functioning in daily life, anxiety symptoms, and depression symptoms. Researchers will compare STEP-UP to referral to community treatment-as-usual mental health services to see if STEP-UP is more effective.

03

Conditions studied

  • Depression, Anxiety
04

Who can participate

Ages eligible
8 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Youth is a patient in a participating community health center.
  • Youths meet criteria for anxiety and / or depression as indexed at baseline assessment by either:

    • research diagnosis of anxiety (Social Anxiety Disorder, Generalized Anxiety Disorder, Separation Anxiety Disorder) and / or depressive disorder (Major Depressive Disorder, Persistent Depressive Disorder).
    • scores in the clinically elevated range on a standardized anxiety and / or depression symptom measure .
  • Youth lives with a legal guardian (hereafter referred to as "parent") >= 50% of the time who consents to study participation.
  • Youth speaks English.
  • Parent speaks English or Spanish.

Exclusion criteria

Exclusion Criteria:

  • Youth requires alternate treatment as indexed by:

    • current Post-Traumatic Stress Disorder symptoms (meets diagnostic criteria in research interview and / or scores in the clinically elevated range on a standardized symptom measure) at baseline.
    • current suicidal ideation with plan at baseline and / or suicidal behavior within the last year.
    • current substance dependence at baseline.
    • experience of physical or sexual abuse within the six months prior to baseline.
    • parent /guardian does not identify anxiety and / or depression as a treatment priority at baseline.
  • Youth is in an active, alternate psychosocial intervention for anxiety or depression that would be concurrent with study participation.
  • Youth is on an unstable regimen of psychotropic medication (i.e., receives medication but has not been at a stable dose for at least 8 weeks, or if medication has been discontinued for less than 4 weeks) at baseline.
  • Youth is receiving lithium or and anti-psychotic medication at baseline.
  • Youth is placed in a special education program for greater than 50% of the school day and / or youth school placement is below the second-grade level at baseline.
  • Youth is placed in foster care at baseline.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
220 participants (estimated)

Study arms

  • Experimental
    STEP-UP

    Behavioral: STEP-UP (transdiagnostic behavioral therapy for pediatric anxiety and depression)

  • Active comparator
    ARC

    Behavioral: ARC (assisted referral to community care)

Interventions

  • BehavioralSTEP-UP (transdiagnostic behavioral therapy for pediatric anxiety and depression)

    STEP-UP consists of 8 to 12 sessions of behavioral therapy for anxiety and / or depression. Skills taught include relaxation, problem solving, and exposure / behavioral activation.

    Also known as: Brief Behavioral Therapy (BBT) for pediatric anxiety and depression

  • BehavioralARC (assisted referral to community care)

    ARC consists of referral to community mental health treatment-as-usual. Families are provided psychoeducation about anxiety and depression and the benefits of treatment, lists of local community providers, and a problem-solving discussion about obstacles to obtaining care.

06

What researchers measure

Primary outcomes

  1. Children's Global Assessment Scale (CGAS)

    Interviewer-rated youth functioning. Scores range from 1 to 100, and higher score indcate superior functioning.

    Time frame: Measured at baseline (Week 0) and follow-up assessments (Week 16 and Week 32)

  2. Pediatric Anxiety Rating Scale (PARS)

    Interviewer-rated symptoms of anxiety disorders, combining parent and youth report

    Time frame: Measured at baseline (Week 0) and follow-up assessments (Week 16 and Week 32). The PARS total severity score ranges from 0 to 30, with higher scores indicating greater anxiety severity.

  3. Children's Depression Rating Scale -- Revised (CDRS-R)

    Interviewer rated symptoms of depressive disorders, combining parent and youth report

    Time frame: Measured at baseline (Week 0) and follow-up assessments (Week 16 and Week 32). The CDRS-R total severity score ranges from 17 to 113, with higher scores indicating greater depression symptom severity.

07

Study locations

1 site
08

References and documents

Publications

  • Rodriguez F, Lynch FL, Gonzalez A, Rozenman M, Dickerson J, O'Keeffe-Rosetti M, Donald J, Hatch B, Barker G, Henninger M, Shaw M, Vaughn KA, Weersing VR. Behavioral telehealth in low-resource primary care settings for anxiety and depression in youth: protocol for a randomized effectiveness-implementation study. Trials. 2026 Jun 3. doi: 10.1186/s13063-026-09589-4. Online ahead of print. PubMed 42237407 ↗

Individual participant data

Plan to share: Yes

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for May 2028, 46 months after the start.

Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 46 months is above that.

Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2024
First posted
Feb 23, 2024
StartActual
Jul 9, 2024
Primary completionEst.
May 31, 2028
CompletionEst.
May 31, 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and description
1 update, last Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Minor edits only
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06273982
Responsible party
Sponsor
First posted
Feb 23, 2024
Start date
Jul 9, 2024
Primary completion
May 31, 2028 (estimated)
Completion
May 31, 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

V. Robin Weersing, PhD
principal investigator · San Diego State University
Frances Lynch, PhD
principal investigator · Kaiser Permanente

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion